CYBN:CC News and Press, CYBIN INC. From 08/17/22

Cybin (NEO: CYBN) (NYSE American: CYBN ), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), along with Clinilabs Drug Development Corporation, has been granted a Schedule I license from the U.S. Drug Enforcement Agency (“DEA”) to support...

Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, and its partner Clinilabs Drug Development Corporation (&...

Cybin (NYSE American: CYBN) (NEO: CYBN) , a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM)”, today announced voting results for each of the matters presented at the company’s annual shareholders’ meeting. There were 71 sharehol...

Cybin Inc. ( NEO:CYBN ) (NYSE AMERICAN:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM ”, is pleased to announce the voting results for each of the mat...

Canada banned psychedelics more than 30 years ago , outlawing the production, sale and use of psychedelics, including psilocybin, for decades. Most countries around the world followed suit and banned psychedelics. However, psychedelic drugs were still quite popular despite being prohibited ...

New research has demonstrated how the uniqueness of the brain of an adolescent may forecast mental-health outcomes. For this study, researchers focused on the adolescent brain, as changes during this period are dynamic and rapid and help form every individual’s uniqueness. Addit...

FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – August 10, 2022 – Toronto’s Center for Addiction and Mental Health (CAMH) just received the first-ever federal grant to study whether the active component of “magic...

Cybin (NEO: CYBN) (NYSE American: CYBN ), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has announced an at-the-market equity program allowing the company to issue and sell up to $35 million of common shares. According to the announcement, the sha...

First paragraph, first sentence of release should read: Cybin Inc. ( NEO: CYBN ) (NYSE American: CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM ”, ann...

Cybin Inc. ( NEO: CYBN ) (NYSE American: CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM ”, announced today that it has established an at-the-market eq...